Navigation Links
Onyx Pharmaceuticals Presents Carfilzomib Data at 53rd American Society of Hematology Annual Meeting
Date:12/12/2011

Oncology Division, Bone Marrow Transplantation & Leukemia Section at the Washington University School of Medicine, who presented the data. "The efficacy and safety results from this study suggest that carfilzomib has the potential to be used in earlier lines of treatment in patients with multiple myeloma."

Patients were divided into two cohorts. In Cohort 1 (n=59), patients received 20mg/m(2) for all treatment cycles.  In Cohort 2 (n=67), patients received a dose-escalating regimen of 20mg/m(2) for the first cycle and 27mg/m(2) for all remaining treatment cycles.

The 59 evaluable patients who received carfilzomib at 20mg/m(2) achieved an ORR of 42 percent and a CBR of 59 percent. This cohort demonstrated a TTP of 8.3 months and a DOR of 13.1 months. The median overall survival (OS) has not yet been reached.  Sixty-six percent of these patients were refractory to their most recent therapy prior to entering the trial.

No new or unexpected adverse events were observed. The most common Grade 3 treatment-emergent adverse events included: anemia (Cohort 1, 12 percent; Cohort 2, 17 percent); thrombocytopenia (Cohort 1, 15 percent; Cohort 2, 11 percent); neutropenia (Cohort 1, 12 percent; Cohort 2, 14 percent); lymphopenia (Cohort 1, 14 percent; Cohort 2, 19 percent); and pneumonia (Cohort 1, 14 percent; Cohort2, 11 percent). Peripheral neuropathy of any grade was infrequent.

"This trial highlights our commitment to understanding carfilzomib across treatment settings," said Ted W. Love, M.D., Executive Vice President and Head of Research and Development and Technical Operations at Onyx Pharmaceuticals. "Efficacy and safety data from this trial was included as part of the New Drug Application (NDA) for carfilzomib that was recently accepted by the U.S. Food and Drug Administration (FDA) under the accelerated approval process for the treatment of patients with relapsed and refractory multiple myeloma."

Abstract #2930:
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Eisai Limited is pleased to support the Canadian Epilepsy Alliance ... in Canada . The comic book, an ... and their parents about epilepsy, the most common neurological disorder ... Canadians. Eisai is guided by a corporate philosophy known as ... is central – there was a need within the epilepsy ...
(Date:8/21/2014)... BURLINGTON, Mass. , Aug. 21, 2014 /PRNewswire/ ... of COPD,  physicians in Brazil ... to follow clinical guidelines and commonly prescribe long-acting ... regimens, although they do so within current severe ... combinations (FDCs) that are expected to launch in ...
(Date:8/21/2014)... N.Y. and HAMBURG, Germany , Aug. 21, 2014 ... is collaborating with Deutsches Elektronen-Synchrotron ( DESY ), a ... , to speed up management and storage of massive ... and Analytics architecture based on IBM software defined ... of data at peak performance and help scientists worldwide ...
Breaking Medicine Technology:Eisai Pleased to Support Canadian Epilepsy Alliance Comic Book that Teaches Children About Epilepsy 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 3DESY and IBM Develop Big Data Architecture for Science 2DESY and IBM Develop Big Data Architecture for Science 3
... Richard and Susan Smith Family,Foundation Announce Renewed Commitment ... 30 The American,Diabetes Association (ADA) has announced ... diabetes genes in mice, and potentially find new,drug ... type 2 diabetes. The,projects will be funded through ...
... a,pioneer in the development of novel products to ... announced that its Vice,President of Research, Johannes Fruehauf, ... World Congress meeting in Boston. His presentation, "Treatment ... 4:25 pm,on Friday, May 2, at the Hilton ...
Cached Medicine Technology:Continued Funding to Help Advance 'Exciting Moment' in Diabetes Research 2Cequent Pharmaceuticals' Johannes Fruehauf, MD, Ph.D., to be Featured Speaker at RNAi World Congress in Boston - May 2, 2008 2Cequent Pharmaceuticals' Johannes Fruehauf, MD, Ph.D., to be Featured Speaker at RNAi World Congress in Boston - May 2, 2008 3
(Date:8/22/2014)... 22, 2014 First Choice Emergency Room ... The facility is located at 8927 Highway 6, Missouri City, ... team is pleased to be a part of the Missouri ... emergency medical care to our neighbors here,” said Dr. Kenneth ... Plantation. , At yesterday’s ribbon cutting with the ...
(Date:8/22/2014)... Teen substance abuse has long been a ... numbers of young adults falling victim to a drug or ... a difference in the community, the new Troubled Teens Toledo ... seeking to overcome their chemical dependency. The helpline is designed ... rehab center to focus on achieving sobriety. , By contacting ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 Dr Murray Grossan ... this snoring cure. , In the October 2014 issue of ... Dr Grossan about his method of treating snoring, and in ... Dr Grossan: "Nearly half of all adults snore occasionally, and ... This is because air passages in the back of the ...
(Date:8/21/2014)... 22, 2014 Os-Monitor.com, an outstanding ... its new employee monitoring software collection ( http://www.os-monitor.com ... also announced that all these high end items ... With the tendency of improving productivity, the employers ... than before. Thus, employee and network monitoring software ...
(Date:8/21/2014)... Florida Hospital Zephyrhills is the first hospital ... in the Tampa Bay area to offer a ... Universal Platform for surgical endoscopy. The technology works ... provides the hospital a standardized solution for surgical ... care. Surgical endoscopy systems, through the collaborative use ...
Breaking Medicine News(10 mins):Health News:First Choice Emergency Room Opens New Facility in Missouri City, Texas 2Health News:New Helpline Provides Hope for Troubled Teens in Toledo 2Health News:Dr Murray Grossan Explains how and why Singing Exercises Stop Snoring 2Health News:Dr Murray Grossan Explains how and why Singing Exercises Stop Snoring 3Health News:New Employee Monitoring Software Collection Unveiled By Os-Monitor.com 2Health News:Florida Hospital Zephyrhills is Elevating Healthcare by Offering the First Olympus Fully-Integrated HD Operating Room in Pasco County 2Health News:Florida Hospital Zephyrhills is Elevating Healthcare by Offering the First Olympus Fully-Integrated HD Operating Room in Pasco County 3
... According ... threat of a lawsuit causes many physicians to delay the adoption of medical innovations., , ... Atlanta, GA (Vocus) May 19, 2010 -- According ... threat of a lawsuit causes many physicians to delay the adoption of medical innovations. More ...
... as likely to develop problem , WEDNESDAY, May 19 ... possibly other similar medications, may prompt long-term hearing loss ... May 18 issue of the Archives of Otolaryngology ... University of Alabama at Birmingham discuss evidence supporting an ...
... ... brings writing tools that authors and writers have requested for years together, in ... York Times Bestselling Author Victor Ostrovsky as a solution for his ongoing needs ... more than 14 million Americans doing creative writing, likely a figure that has ...
... Malaga (UMA) have analysed the presence of voice disorders in ... statistic: 62.7% of the Early Childhood and Primary Education teaching ... basis. Professions such as teaching require a ... with vocal overload. "Our aim was to analyse the vocal ...
... (May 19, 2010) A Phase I clinical trial ... class of drugs that inhibit cyclin-dependent kinases, demonstrated the ... lymphocytic leukemia (CLL). Cyclin-dependent kinases are enzymatic proteins that ... and are thought to play key roles in the ...
... ... for the deadly childhood crippler spinal muscular atrophy (SMA), is awarding a $250,000 research ... professor of The Ohio State University. , ... (PRWEB) May 19, 2010 -- Richmond, Virginia-based FightSMA, a nonprofit ...
Cached Medicine News:Health News:Lawsuit Fears Hinder Physician Adoption of Medical Innovations, Survey Finds 2Health News:Lawsuit Fears Hinder Physician Adoption of Medical Innovations, Survey Finds 3Health News:Viagra Linked to Hearing Loss 2Health News:TheBookPatch.com Launches: Writers Have Free Online Destination with Myriad Tools; Users Can Print One Book at a Time 2Health News:TheBookPatch.com Launches: Writers Have Free Online Destination with Myriad Tools; Users Can Print One Book at a Time 3Health News:More than 60 percent of teachers have voice problems 2Health News:Drug in new class of targeted therapies shows early promise against blood-related cancers 2Health News:Drug in new class of targeted therapies shows early promise against blood-related cancers 3Health News:FightSMA Awards $250,000 Grant to Gene Researcher at The Ohio State University 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: